Benjamin Leder is an Endocrinology/Metabolic physician affiliated with Massachusetts General Hospital. OpenAlex indexes 148 publications with 7,960 citations (h-index 42); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Combined Anabolic Therapy
Sponsor: Massachusetts General Hospital
- Mechanisms of Anabolic Osteoporosis Therapy
Sponsor: Massachusetts General Hospital
- Anabolic Therapy in Postmenopausal Osteoporosis
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
7 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
84.2%Parathyroid Hormone Analog44.7%Forteo100%Part D<11 patientsl-Thyroxine39.5%Levothyroxine Sodium100%Part D<11 patientsGenitourinary & hormones
15.8%Estrogen Agonist/Antagonist15.8%Raloxifene Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
10 NIH research awards on record, funded 1999–2024 per NIH RePORTER. The latest:
- Combined Anabolic Therapy in Postmenopausal Osteoporosis
Massachusetts General Hospital
FY2024$587,840R21AR083567 - Limited-duration anabolic therapy in postmenopausal osteoporosis
Massachusetts General Hospital
FY2023$181,120R21AR079718 - Limited-duration anabolic therapy in postmenopausal osteoporosis
Massachusetts General Hospital
FY2023$80,000R21AR079718
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
James Januzzi, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
David Scadden, MD
Massachusetts General Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”